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Abstract
Human (HRSV) and bovine (BRSV) respiratory syncytial viruses (RSV) are two closely
related viruses, which are the most important causative agents of respiratory tract infections of
young children and calves, respectively. BRSV vaccines have been available for nearly 2
decades. They probably have reduced the prevalence of RSV infection but their efficacy needs
improvement. In contrast, despite decades of research, there is no currently licensed vaccine
for the prevention of HRSV disease. Development of a HRSV vaccine for infants has been
hindered by the lack of a relevant animal model that develops disease, the need to immunize
immunologically immature young infants, the difficulty for live vaccines to find the right
balance between attenuation and immunogenicity, and the risk of vaccine-associated disease.
During the past 15 years, intensive research into a HRSV vaccine has yielded vaccine
candidates, which have been evaluated in animal models and, for some of them, in clinical
trials in humans. Recent formulations have focused on subunit vaccines with specific CD4+
Th-1 immune response-activating adjuvants and on genetically engineered live attenuated
vaccines. It is likely that different HRSV vaccines and/or combinations of vaccines used
sequentially will be needed for the various populations at risk. This review discusses the recent
advances in RSV vaccine development.
Keywords: Vaccine; Respiratory syncytial virus; RSV
ARTICLE IN PRESS
Corresponding author. Tel.: +335 61 19 32 98; fax: +33 5 61 19 38 34.
E-mail address: g.meyer@envt.fr (G. Meyer).
Re´sume´
Les virus respiratoires syncytial humain (HRSV) et bovin (BRSV) sont des agents
pathoge`nes e´troitement apparente´s, respectivement responsables d’affections de l’appareil
respiratoire chez les jeunes enfants et chez les veaux. Des vaccins contre le BRSV sont
commercialise´s depuis deux de´cennies et ont probablement permis de limiter la pre´valence de
l’infection. Leur efficacite´ doit cependant eˆtre ame´liore´e. La situation est diffe´rente pour le
HRSV puisqu’ aucun vaccin n’est actuellement disponible sur le marche´, malgre´ de
nombreuses recherches. La vaccination contre le HRSV se heurte a` plusieurs difficulte´s, a`
savoir l’absence de mode`le animal d’infection qui reproduise la pathologie chez l’enfant, la
ne´cessite´ de vacciner de jeunes enfants dont le syste`me immunitaire n’est pas totalement
fonctionnel, la difficulte´ d’obtenir des vaccins vivants pre´sentant un compromis efficace entre
atte´nuation et immunoge´nicite´ et les de´fauts d’innocuite´ de certains vaccins. Pendant ces 15
dernie`res anne´es, des efforts intensifs de recherche ont permis de de´velopper de nouveaux
candidats qui ont e´te´ e´value´s dans des mode`les animaux et, pour certains, chez l’homme. Les
recherches se sont concentre´es sur la production de vaccins sous-unitaires avec des adjuvants
orientant la re´ponse cellulaire T CD4+ vers une re´ponse de type Th-1 et sur des vaccins
vivants atte´nue´s construits par ge´nie ge´ne´tique. Les strate´gies vaccinales visent a` l’utilisation
prochaine de diffe´rents vaccins en fonction de la population a` risque et/ou des combinaisons
se´quentielles de vaccins de diffe´rents types. Cette revue fait la synthe`se des avance´es re´centes
en terme de nouveaux vaccins contre le BRSV et le HRSV.
Mots cle´s: Vaccins; Virus respiratoire syncitial; VRS
1. Introduction
Human (HRSV) and bovine (BRSV) respiratory syncytial viruses (RSV) are two
closely related, highly infectious, worldwide prevalent viruses that are the leading
cause of serious respiratory tract disease in children and calves, respectively. RSV
infection is extremely common in the first year of life. By 24 months of age, virtually
all children have been infected by HRSV at least once, and about half have
experienced two infections [1]. In the United States, about 70% of bronchiolitis
hospitalizations are associated with HRSV infection [2]. HRSV has been estimated
to account for 85,000 to 144,000 hospitalizations annually in infants of less than 1
year of age with an associated cost of $300,000,000 per year [3]. In Europe, RSV
accounts for 42–45% of hospital admissions with low respiratory tract infection in
children younger than 2 years of age [4]. HRSV mortality has been estimated as
0.005–0.02% in developed countries, due to the efficacy of symptomatic ventilation
treatment. However, severe HRSV infection in the first 6 months of life is often
followed by recurrent childhood wheezing, [5,6] or asthma [7]. There also are
variable contradictory reports of an association with atopic disease [8,9]. HRSV
reinfection is also gaining recognition as an important cause of disease in adults,
especially the elderly [10], in patients with underlying cardiopulmonary illnesses [11],
and in immunosuppressed patients, particularly bone marrow transplant patients
[12,13].
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Similarly, the frequency and seriousness of BRSV diseases are regarded as the
principal health problem in calf rearing world-wide, as intensification of farming
industry is developing. The frequency of BRSV infections is very high in cattle less
than 1-year-old [14–17] and the virus might be responsible for more than 60% of the
epizootic respiratory diseases observed in dairy herds [14,18,19] and up to 70% in
beef herds [20,21]. Mortality of BRSV ranged generally between 2% and 3% but can
reach up to 20% in some outbreaks.
The fight against HRSV is considered by the WHO as a priority and prevention of
BRSV is a major concern in farming industry. Several BRSV vaccines have been
commercialized for many years but there is a need to develop second generation
vaccines with a greater efficacy in the presence of maternal antibodies (Abs) and
capable of inducing a more durable protection. In contrast to BRSV, no vaccines are
yet available against HRSV. Human vaccine development has been primarily
hampered by disease potentiation observed after vaccination with an experimental
RSV inactivated vaccine but other obstacles to vaccination exist, such as the lack of
a relevant animal model that mimicks the natural disease in humans and the need to
immunize immunologically immature young infants. This review discusses recent
advances that have been obtained these last years to develop a new generation of safe
and effective HRSV and BRSV vaccines.
2. Acquired immunity to RSV infection
BRSV and HRSV are members of the genus Pneumovirus in the family
Paramyxoviridae. The virion is wrapped into a lipid envelope derived from the host
plasma membrane that contains three viral transmembrane surface glycoproteins
organized separately into spikes on the surface of the virion (Fig. 1). These
glycoproteins are the attachment glycoprotein (G), the fusion protein (F) and the
small hydrophobic protein (SH) [22]. The F and G glycoproteins are major antigens
and were consequently extensively used in vaccine development. The envelope
encloses a helical nucleocapsid, which consists of the nucleoprotein (N), the
phosphoprotein (P), the viral RNA-dependent polymerase protein (L) and the
genomic RNA. In addition, there is a matrix M protein that is thought to form a
layer on the inner face of the envelope and a transcriptional anti-termination factor
M2-1. The genome also encodes an RNA regulatory protein M2-2 and two non-
structural proteins, NS1 and NS2 (Fig. 1). The viral genome, which consists of a
negative-sense non-segmented single-stranded RNA genome of approximately
15,200 nucleotides, is first transcribed into 10 mRNAs in a sequential fashion from
the 30 to the 50 end according to a polar transcription gradient [22]. The 10 mRNAs
are then translated into 11 viral proteins, the M2 gene coding for two proteins M2-1
and M2-2. The properties of RSV proteins are shown in Table 1.
RSV replicates primarily in the superficial layer of the respiratory ciliated
epithelium and to a lesser extent in type II pneumocytes [23,24]. No cytopathology is
observed in infected human as well as bovine airway epithelial cells, suggesting that












Fig. 1. Diagram of respiratory syncytial virus.
Table 1
RSV protein functions
Protein Mr (kD) Functions
NS1: Non-structural protein 1 13.8 Inhibition of and resistance to IFN-a/b
Host tropism
NS2: Non-structural protein 2 14.5 Inhibition of and resistance to IFN-aXb
Host tropism
G: G protein 70 Attachment
Host tropism
Escape immunity by binding to neutralizing Abs
(G secreted form)?
F: Fusion protein 90 Attachment and membrane fusion
Host tropism
SH: Small hydrophobic protein 7.5–60 Unknown function
M: Matrix protein 25 Virion assembly
M2-1: Matrix protein 2-1 22 Transcription anti-termination factor
M2-2: Matrix protein 2-2 11 RNA regulatory protein
N: Nucleoprotein 45 Protection of genomic and antigenomic RNA
Transition from transcription to replication
P: Phosphoprotein 33 Polymerase co-factor
Host tropism (HRSV)
L: Polymerase protein 250 RNA dependant RNA polymerase
defence mechanisms against RSV infection involve overlapping aspects of innate and
acquired immunity where the magnitude and quality of the acquired immunity
response is dependent on signals derived from the innate response. Indeed, the
pattern of cytokine and chemokine expression induced during the innate response
activates immune cell trafficking (macrophages, eosinophils, basophils, neutrophils
and NK cells) to sites of infection, regulates B and T cell survival, and may enhance
virus clearance or exacerbate disease. Features of the innate response were
extensively studied these last few years and recently reviewed for HRSV [26–29]
and BRSV [30]. Consequently, despite their importance, they will not be discussed in
this paper.
Acquired immunity is mediated by B and T cell responses that endow diversity of
antigen recognition, memory and immune self-tolerance. Established RSV infection
is controlled primarily by the T cell response, which protects the host from severe
RSV disease and limits virus shedding [31]. Both Th1 and Th2 T cell subsets are
important for virus clearance but both also are connected with pathology and illness
[32,33]. HLA class I or class II-restricted T cell HRSV epitopes have been described
in the N, M, NS2, M2-1, F and G proteins [34–44]. HLA class II-restricted T cell
responses to the F protein were studied in more detail by using a set of overlapping
peptides, which resulted in the detection of multiple antigenic regions spanning the F
protein [45]. Several studies have underlined the role of CD4+ T cells in RSV
immunity and disease pathogenesis. CD4+ T cells express a spectrum of cytokines
required for cell-mediated immune response, including IL-2 and IFN-g. In BALB/C
mice, primary infection induces a mixed Th-1/Th-2-type cytokine response with
limited disease and it appears that early INF-g expression is important in controlling
the Th-1/Th-2 cytokine balance [27,46,47]. Absence of INF-g early after primary
infection or during subsequent RSV infections results in a predominant Th-2-type
cytokine response and increased disease severity [46,48,49]. Thus, the response of
CD4+ T cells and the pattern of cytokines they produce affect the outcome of
immunity and disease pathogenesis.
The class I restricted CD8+ cytotoxic T lymphocyte (CTL) response is targeted
against several proteins [50,51], the M2, F and N proteins being the major targets
[44,52,53]. In mice, M2 primes strong CTL responses but also severe disease
enhancement after RSV challenge [32]. In BALB/c mice the G protein is generally
considered to not induce CTL [51,54,55] despite recent contradictory results [56].
Studies in humans have also been unable to demonstrate G-specific CTLs (4),
whereas G-specific CD4+ T cells are readily detectable [57]. In contrast, in calves, it
has been shown that G-specific CD8+ T cells can be detected after BRSV challenge
[58]. CTLs have a major role in the clearance of virus infection and there is a robust
expansion of RSV-specific CD8+ T lymphocytes in the lung. However, despite a
rapid response, RSV-specific pulmonary CTLs with impaired cytokine secretion and
cytotoxicity have been described [59].
If cell-mediated immunity is essential for virus clearance following acute infection,
the antibody (Ab) response generally protects against reinfection. This is a major
goal when developing vaccines against RSV. The humoral response is essentially
directed against the F and G proteins, whose various neutralizing epitopes have been
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mapped and characterized among RSV subtypes [60–67]. Selection of RSV escape
mutants was also shown to be associated with amino acid substitution in these
antigenic domains [60,61,68,69]. Nasal Ab levels are probably essential for
protection against infection of the upper airway. Resistance to infection in the
upper airways is mediated by transitory and local expression of secretory IgA, but
more durable resistance is probably associated with IgM, and especially neutralizing
IgG Abs [70]. Serum Abs were shown to play a significant role against lower airway
infection [71].
The inability of the host to mount an effective immune memory response allows
the occurrence of successive reinfections and constitutes a major obstacle to the
efficacy of vaccination. The mechanisms involved in virus escape from the immune
response are not well understood and could include an ineffective B cell response to
RSV in the nasal cavity, probably due to a poor IFN-ab induction by the virus and/
or a defective T cell memory compartment. Contact-dependent mechanisms, IL-1
receptor antagonist, IFN-a, IFN-b and IFN-g together have each been implicated
[28,72–75]. Alteration of dendritic cells (DCs) by RSV infection has also been
proposed to explain why protection after natural RSV infection is incomplete and of
short duration. However, infection of human monocyte-derived DCs (10–30%) by
RSV was shown not to be effective and not to alter cell viability, suggesting that the
virus does not significantly interfere with the function of these cells [76].
3. Challenges and difficulties of RSV vaccine research
Despite the importance of HRSV infection, there are currently no licensed
vaccines for prevention of this disease. From 1960 to 1980, trials of several candidate
HRSV vaccines failed to attain the desired safety or to induce protection against
natural infection, either by insufficient immunogenicity or by inducing exaggerated
disease on natural exposure to the virus. Since the 1980s, there has been an intensive
effort to develop an effective and safe RSV vaccine based on the molecular virology
of RSV. Difficulties of vaccine development stem from the virus but also from the
host. These difficulties include the lack of a relevant animal model, the need to
immunize immunologically immature young infants with maternal RSV antibodies,
the impact of RSV variability on vaccination and the risk of vaccine-associated
disease enhancement. These problems also partially exist for BRSV vaccines. Since
acceptation of the risk is different for livestock, several BRSV vaccines have
nevertheless been commercialized.
3.1. Animal models
An accurate evaluation of the safety and efficacy of a RSV vaccine can only be
made in clinical studies involving the target population, but pre-clinical studies need
to be performed in animal models. Advantages and disadvantages of RSV animal
models have recently been discussed [27].
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For HRSV, mice and cotton rats, which are the models used currently, are
semipermissive for viral replication and do not exhibit authentic RSV disease. This
complicates the interpretation of clinical protection afforded by vaccines.
Chimpanzees are the only experimental animals that approach humans in
permissiveness to HRSV replication and disease [77–79] but their availability is
limited. As HRSV and BRSV show similarity in epidemiological and clinical aspects
of infection, BRSV infection in calves is also a good comparative model for the study
of HRSV.
For BRSV studies, calves are the natural hosts and are used for vaccine
evaluation. However, many models of infection using various concentrations of cell-
culture-passaged virus by different routes failed to reproduce severe clinical signs or
lesions as observed in natural conditions [80,81]. Consequently, clinical differences
between vaccinated and non-vaccinated groups after challenge are frequently non-
significant and protection is often demonstrated on reduction of virus titres in
vaccinated calves. Recently, an improved clinical model of infection has been
developed by using as inoculum a preparation of BRSV previously replicated in new-
born calves [82–84]. Despite this progress, clinical variability between calves remains
high and hampers statistical interpretation of the results. Finally, due to the high
prevalence of infection and considering the age of the animals to vaccine,
experimentations also ought to be done in calves possessing maternally derived Abs.
3.2. Age of hosts
An effective RSV vaccine has to stimulate an effective immune response during the
first months of life when the peak incidence of severe disease occurs. However,
immune response to infection or immunization exhibited by neonates is reduced and
probably stems from multiple factors, including immunological immaturity [85,86]
with limited B cell repertoire, inefficient mechanisms of antigen (Ag) presentation
and T cell help, and inhibition by passively acquired maternal Abs [87]. The principal
method of transfer of antibodies (Abs) from human mothers to infants is via the
transplacental route, starting at 28 weeks of gestation and increasing until the time of
birth. In ruminants, there is no transplacental transfer of Abs and the neonate lacks
significant levels of serum Abs until it absorbs them from colostrum or breast milk
via enteric Ab receptors. In the two cases, the IgG1 subclass of Abs is preferentially
transferred, with little IgM, IgA, or IgE transferred. The role of maternal Abs during
RSV infection or immunization is not clearly defined. Data suggest that passive Abs
inhibit both the quantitative level and functional quality of mucosal and systemic Ab
responses after natural infection or immunization in both mice, humans and calves
[87,88]. Passively trasferred Abs are particularly suppressive of responses to RSV
subunit vaccine candidates [89] but also to live vaccinia virus vectors that express the
RSV surface glycoproteins [90,91]. Despite this inhibitory effect, protective efficacy
against wt HRSV challenge was induced in mice or chimpanzees [87] by live
attenuated HRSV infection in the presence of RSV Abs. In mice, CD4+ and CD8+
T cells are required for this protection [87]. Therefore, priming of the B cell
repertoire for secondary Ab responses may occur during RSV passive/active
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immunization experiments, even when primary Ab responses are suppressed at levels
that are lower than detectable limits. This was also partially described for BRSV by
Kimman et al. [88] who showed, in addition, that both the incidence and severity of
disease were inversely related to the maternal Ab level, suggesting clinical protection
by these Abs during natural infection [17].
Since maternal Ab inhibitory effect predominates in the lower respiratory tract
[92], the most commonly admitted strategy today to overcome Ab-mediated
immunosuppression is mucosal immunization, especially with live attenuated
viruses. For BRSV, protection was afforded by intra nasal immunization with live
virus, both in calves with and without maternal Abs [93]. This protection was
associated with a strong and rapid mucosal Ab memory response. In contrast,
intramuscular immunization with killed or live virus vaccines in the presence of
maternal Abs proved to be little effective in inducing memory and protection against
virus shedding [93]. Maternal immunization could be an alternate strategy to protect
newborn calves from infection. One assay of vaccination of pregnant cows with
BRSV live vaccines showed a boost of the systemic humoral and cellular responses to
BRSV in cows and of the level of BRSV IgG1 in the colostrum [94]. A similar
strategy for HRSV vaccination of pregnant women has been discussed but the fear
was raised that some antigens might cross the placental barrier and predispose the
infant to allergic responses because the foetal cytokine milieu exhibits a predominant
Th-2-like bias [87].
3.3. RSV variability
The variability of RSV has a major impact on vaccine development, especially
when addressing the development of sub-unit vaccines, which contain only one or a
few viral epitopes. The antigenic and genetic variability among independent isolates
of HRSV from different infected hosts or geographic regions has been extensively
documented, and the existence of two major groups (A and B), as well as additional
variability within each group, have been clearly established [95,96]. The most
extensive variability was found in the attachment glycoprotein G, which differs by up
to 45% in its aminoacid (aa) sequence between the two groups. Studies in animals
and in humans have demonstrated that this difference should be taken into account
in the development of vaccines. Thus, immunization with individual F or G proteins
in animals has shown that the F protein is broadly cross-protective, whereas the G
protein mostly provides group-specific protection [97–99]. A subunit vaccine based
on G protein will therefore need G proteins from both antigenic groups to provide
full protection.
The extent of antigenic variation observed among BRSV isolates is considerably
less than that observed with HRSV isolates. Four antigenic subgroups (A, B, AB,
untyped) have been identified in BRSV but they may only represent variants of a
single major antigenic group [66,100–103]. Thus, the variability of the nucleotide
sequence of the highly variable G gene does not exceed 15% between independent
BRSV isolates [81,104]. The existence of six BRSV genetic subgroups based on the
sequence of G and of five subgroups based on that of F or N has nevertheless been
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established [104]. These classifications show a spatial clustering and a continuous
evolution of BRSV isolates, probably driven by selective pressure as a result of the
immune response induced by vaccination [104]. The biological significance of these
subgroups remains unclear. Polyclonal sera obtained from calves vaccinated with the
BRSV G protein from a subgroup A virus recognized a different subgroup A isolate
but failed to recognize a subgroup B or an untyped isolate [105]. Moreover,
recognition of a subgroup AB isolate was weaker than that of the subgroup A
isolate. In contrast, vaccination with a strain isolated in 1969 and classified in genetic
group II protected calves against challenge with a BRSV strain isolated in 2003 and
belonging to the distant genetic group V (unpublished observation).
Studies to explain the molecular bases of RNA virus genetic variability showed
that these viruses evolve as dynamic distributions of closely related mutant genomes
that exist in equilibrium around a theoretical consensus sequence. Such quasispecies
structure was observed in vitro and in vivo for BRSV with mutation frequencies
ranging from 6.8 104 to 10.1 104 substitutions per nucleotide [106]. This
genetic heterogeneity is shaped by the selective pressures of the environment and
provides great adaptability among virus populations. For example, the emergence of
HRSV escape mutants after passive administration of an anti-F monoclonal
neutralizing Ab (palivizumab) has been observed both in vivo and in vitro [107,108].
It was also shown that only two aa changes (Arg 188 and Lys 192) in a dominant T
cell epitope of the HRSV G protein were able to abolish the protection induced by
this protein in a mouse challenge model [109]. The consequence of the existence of
such a quasispecies on RSV vaccination is not clear to date but we can presume that
an infecting virus will more readily escape the immune response directed against only
one epitope than against several epitopes. In addition, a live attenuated vaccine
strain with only one attenuation mutation will be more highly prone to reversion to
virulence than a strain with several attenuation mutations.
3.4. Vaccine-associated disease enhancement
In fact, human vaccine development has essentially been hampered by HRSV
vaccine-associated disease. In the 1960s, a formalin-inactivated RSV (FI-RSV)
vaccine was evaluated in infants and children. It was found to be poorly protective
and, unexpectedly, was associated with an increased frequency and severity of RSV
disease upon subsequent natural infection [27,110,111]. Early studies suggested that
FI-RSV induced high titres of RSV serum Abs as measured by ELISA but relatively
low levels of RSV-neutralizing activity, suggesting that formalin inactivation
selectively altered the protective epitopes located within the F and G surface
glycoproteins [111]. In addition, lymphocytes from FI-RSV vaccinees showed a
greater proliferative response to RSV antigens than did those obtained from children
naturally infected with wt RSV, and a peripheral eosinophilia was observed in some
FI-RSV vaccinees [111]. Mechanisms responsible for the FI-RSV vaccine-associated
disease enhancement have been extensively studied and discussed [27,28,111] but
they still are not completely understood. In mice, disease potentiation by FI-RSV
was shown to depend on an increased stimulation of Th-2 CD4+ T lymphocytes
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[111–113], while RSV-specific Abs were not sufficient to cause disease enhancement
[114]. Further studies revealed a marked increase in the expression of Th-2-type
cytokines (IL-5, IL-13, and IL-10) and a reduced expression of IL-12 in FI-RSV-
immunized mice, indicating a Th-2 bias and an increase in proinflammatory
cytokines [115]. In addition, the mouse model has provided evidence for down-
regulation of CD8+ and CD4+ T cell responses [48,115,116]. Based upon these
data, it was postulated that FI-RSV vaccinees remained susceptible to infection with
wt RSV because vaccination produced inadequate levels of neutralizing Abs in serum
and did not induce local immunity. Once the vaccinees were infected with wt RSV,
the virus was not readily cleared because FI-RSV had not primed for CTL responses.
In addition, immunization with FI-RSV primed for a Th-2-like response, an influx of
lymphocytes and eosinophils, and the possible release of additional mediators
resulting in local inflammation and bronchoconstriction.
By using recombinant vaccinia viruses (VV) expressing individual RSV proteins, it
was shown that VV expressing the G glycoprotein primed a Th-2 cell response and
led to secondary RSV disease [117], while VV expressing the F glycoprotein primed a
Th-1 response including CTLs [118]. In addition, VV-M2 primed for a secondary
RSV disease characterized by a strong CTL response [27]. However, immunization
with VV recombinants expressing individual RSV proteins did not lead to enhanced
disease of the same severity as that seen after FI-RSV vaccination. Also,
immunization with the G protein was shown not to be necessary for FI-RSV-
enhanced disease [119,120]. In non-human primates, patterns of FI-RSV-induced
disease augmentation were generally similar to those seen in other animal species
[121]. However, facilitation of RSV infection in cell culture by serum Ab from
animals immunized with FI-RSV suggests that Ab might play a role in FI-RSV
enhancement of disease [122].
The immunopathological FI-RSV model was also described for BRSV in calves,
the natural host. Results showed that immunization with FI-BRSV generally
resulted in an adequate neutralizing Ab response [123] and mainly primed
inflammatory responses, which were associated with an eosinophilic influx into the
bronchial alveolar lung fluid and lung tissues and high levels of immunoglobulin E
serum Abs [82,124,125]. In addition, the FI-BRSV vaccine was not able to effici-
ently prime long-term T cell memory and several response patterns (Th-l/Th-2) seem
to co-exist during BRSV infection. [58]. It has been suggested that the
immunopathogenic immune response to BRSV may be mediated by the deposition
of immune complexes and by complement activation in the lungs [126] and/or by the
induction of a strong Th-2 biased immune response [112,114,115,119]. Immuno-
pathological vaccine-associated disease was also demonstrated with commercialized
inactivated BRSV vaccines after experimental [127] or natural [128,129] BRSV
infections.
Finally, the clinical experience with FI-RSV and the information gleaned from
animal models of disease enhancement suggest that a good vaccine should induce
protective levels of neutralizing Abs as well as a strong CD8+ RSV-specific
cytotoxic T cell response and elicit a pattern of CD4+ T cell response similar to that
elicited by wt RSV.
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4. Human and bovine respiratory syncytial virus vaccine development
4.1. Inactivated whole virus vaccines
In humans, the risk of disease enhancement has made vaccination of RSV-naı¨ve
infants with whole inactivated virus unacceptable to many registration authorities.
However, the fact that disease enhancement is not observed if FI-RSV is
administered as a boost to already infected animals suggests that an RSV subunit
vaccine would be suitable to boost immunity in previously infected individuals
including the elderly and individuals at high risk for RSV disease [130]. In addition,
several sub-unit vaccines were shown not to be associated with disease enhancement.
It is also possible that novel immunization strategies that combine non-replicating
subunit vaccines with cytokines or new adjuvants will permit to drive the immune
response towards a Th-1 pathway [131].
The situation is quite different in veterinary medicine. Despite a few observations
of respiratory disease enhancement after infection in cattle previously vaccinated
with inactivated virus [124,125,128,129], whole inactivated BRSV vaccines have been
available for nearly 2 decades. Experimental studies have documented the efficacy of
the new, recently licensed inactivated BRSV vaccines in significantly reducing the
prevalence and severity of respiratory disease in cattle that were challenged with a
virulent field isolate, and no disease enhancement was observed [82,127]. In addition,
although millions of doses of vaccines have been used in the field, no immune-
mediated enhancement of disease has been reported to date by pharmacovigilance
authorities. One explanation could be that the current inactivated vaccines are
adjuvanted with Quillaja saponin, which was shown to stimulate CD8+ and Th-1
CD4+ effector T cells. The dose of BRSV antigen, differences in formulation and
inactivation process as well as differences in adjuvants may be responsible for the
induction of different immune responses to BRSV vaccines [123,132]. It is therefore
difficult to draw a general conclusion about the protective or disease-enhancing
properties of whole inactivated BRSV vaccines.
4.2. Subunit and synthetic vaccines
4.2.1. Antigens
Research on HRSV vaccines has essentially focused on subunit vaccines including
viral proteins or peptides. Two approaches have been developed to produce subunit
vaccines. The first approach was to use chimeric FG glycoprotein or full-length F
protein (PFP-1, PFP-2 and PFP-3) purified from infected cells. These vaccines were
first tested in a variety of rodent and primate models [89,114,133–137]. In rodents,
when administered parenterally, they were shown to protect the lower respiratory
tract but not the upper respiratory tract against RSV challenge [114,133,135,136].
Intranasal immunization with PFP-1 protected the upper respiratory tract against
challenge [138], while the combination of intranasal and subsequent parenteral
immunization provided protection of both the upper and lower respiratory tracts as
observed after wild-type virus infection [138]. However, enhanced pulmonary
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pathologic changes were observed with the FG and PFP vaccine candidates in cotton
rats, with high ratios of F-binding Abs to RSV-neutralizing Abs [114,139]. In
African green monkeys, the FG candidate vaccine delivered intramuscularly was
found to be safe but unfortunately induced only low levels of serum RSV-
neutralizing Abs and afforded minimal protection of the lower respiratory tract to
challenge with wt virus [114]. These candidates were finally tested in human clinical
trials involving elderly volunteers [140,141], pregnant women [142] and children
older than 1 year [143–147]. The PFP vaccines were shown to be safe and moderately
immunogenic in pregnant women [142], children with chronic lung disease [146,147]
and the elderly [140,141,146,147]. A meta-analysis was performed on PFP vaccine
safety and efficacy studies that suggested that RSV subunit vaccines reduced the
overall incidence of RSV infections, a conclusion which however needs to be
confirmed by large field trials because of doubts about the appropriateness of
pooling samples from different studies, the risk of publication biases and the fact
that the clinically important RSV lower respiratory tract infection was not reduced
in the vaccinees [4].
The second approach followed for the development of a subunit HRSV vaccine
was that of BBG2Na, a recombinant fusion protein produced in bacteria that
consisted of the central antigenic domain (amino acids 130–230) of the HRSV G
protein of subgroup A fused to the C-terminal end of the albumin-binding domain of
the streptococcal G protein [148]. BBG2Na was proved to be safe and moderately
immunogenic in adult mice and in neonatal mice with or without maternal Abs
[148–153]. Protective immune responses were demonstrated against both HRSV
subgroups A and B but the duration of protective immunity against group B was
insufficient to prevent infection for the duration of the epidemic season [154].
Priming of neonatal mice with BBG2Na formulated in either Al(OH)(3) or TiterMax
(a Th-1-driving adjuvant) resulted in predominant Th-2- and Th-1-like responses,
respectively. Despite these differences, no lung immunopathology was observed after
challenge of the animals vaccinated with either vaccine candidate [150]. It has been
suggested that the absence of disease enhancement may have been related to the fact
that the G moiety in BBG2Na was not glycosylated, as it was produced in bacteria.
Finally, unconclusive results about immunopathological safety of alum-adsorbed
BBG2Na were obtained in infant macaques, leading to a request for more extensive
studies before proceeding to clinical trials in seronegative infants [155]. BBG2Na was
nevertheless investigated in a phase III clinical trial in adult volunteers, but the trial
had to be stopped due to the occurrence of unexpected adverse events.
Many other studies on the development of RSV subunit vaccines have been
published but these newer vaccine candidates are less far along in development. They
include the RSV N protein (S. Riffault and J.-F. Elloue¨t, pers. comm.), a
baculovirus-expressed chimeric protein created by fusing the RSV F and G ORFs
[156], as well as synthetic peptides. Recently, peptide G20, a 69 amino acids peptide
derived from the G protein deleted of the T helper cell immunopathogenic epitope,
generated a highly protective Ab response against HRSV challenge in Balb/c mice
[157]. A new recombinant protein was also obtained by fusing the N-terminus of the
chimeric CTL epitope F/M2(81-95) from HRSV to the disulphide bond isomerase
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used as a carrier. Administered by intraperitoneal injections into mice, the fusion
protein elicited effective virus-specific CTL responses as well as protective immunity
without association with enhanced disease [158]. The same M2 epitope was also
fused to HRSV G protein fragment 125–225: the resultant fusion protein was shown
to induce not only humoral but also cellular immunity and a balanced IgG1/IgG2a
response [159].
4.2.2. Adjuvants
Whatever the purified recombinant protein or peptide used, it usually requires the
co-administration of an adjuvant when injected alone, in order to elicit optimal
immune responses. For RSV vaccines, new adjuvants are specifically tested to
activate neutralizing Ab, CD8+ CTL and Th-1 CD4+ T cell responses, as well as
mucosal immune responses.
Experimentally, several adjuvants were tested with some success: cholera toxin
(CT), caprylic/capric glycerides (CCG) [160] and polyoxyethylene-20-sorbitan
monolaurate (PS) [161] were tested with FG or PFP proteins, bacterial outer
membrane vesicles (OMV) with inactivated RSV [162] and dimethyl dioctadecy-
lammonium bromide (DDA) with BBG2Na [163]. A major concern for the use of
enterotoxins is related to their toxicity especially for the central nervous system [164].
Quillaja saponi is the only adjuvant used in current commercialized inactivated
BRSV vaccines. These vaccines were shown to reduce clinical disease [165] and virus
shedding following experimental BRSV challenge, even in calves with high levels of
maternal Abs at the time of vaccination [132,166,167]. The purified fraction 21 of
Quillaja saponaria (QS-21) was also tested with the F protein of HRSV in Balb/c
mice, in comparison with aluminium hydroxide (F/AlOH) adjuvant and wild-type
infection [137]. Results showed that F/QS-21 induced a greater titre of seric virus-
neutralizing activity than F/AlOH and local pulmonary immune responses similar to
those obtained after experimental infection. It was also shown that QS-21 synergized
with recombinant interleukin-12 to create a potent adjuvant formulation for the F
protein of HRSV [168].
The immunostimulating complexes (ISCOMs) also are strong adjuvant and
delivery systems for parenteral as well as mucosal immunization. The ISCOM
technology relies on the multimeric presentation of an Ag with adjuvant molecules in
a symmetrical particle composed of Quillaja saponins, cholesterol, phospholipids,
and protein. ISCOMs were shown to have strong mucosal adjuvant activity when
used by the nasal route. A panel of ISCOMs including the F and G HRSV
glycoproteins and containing different Quillaja saponin fractions were tested for
their capacity to induce innate and acquired immune responses [169]. All
combinations induced various degrees of Th-1 biased responses in mice, with
prominent production of IFN-g and strong induction of IgG2a Abs. For BRSV, the
protection induced by ISCOMs was evaluated and compared with that of a
commercial inactivated vaccine in calves with BRSV-specific maternal Abs. The
results showed that, in contrast to the inactivated vaccine, ISCOMs could overcome
the suppressive effect of maternal Abs and induce a strong clinical and virological
protection against a BRSV challenge [170]. HRSV ISCOM vaccines also induced
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protection in the presence of passive Abs in animal models but the feasibility of this
approach in human neonates is unclear at this time.
Another category of compounds with significant promise as adjuvants for subunit
vaccine antigens is synthetic oligodeoxynucleotides (ODN) containing unmethylated
CpG dinucleotides. These compounds were reported to have adjuvant activity in
mice and to drive the immune response towards a Th-1 phenotype [171,172]. The
feasibility of using ODN–CpG motifs for subunit vaccines against HRSV or BRSV
was tested in different models. In BALB/c mice, subunit HRSV F and FI-BRSV
vaccines were compared with control vaccines [173]. Co-administration of these two
vaccines with CpG–ODN resulted in statistically significant increases in serum
neutralization titres, an enhanced generation of splenic antigen-dependent killer
cell precursors, an accelerated clearance of infectious virus from lungs and,
finally, an enhanced ability to elicit Th-1 immune responses. Cotton rats immunized
with HRSV F protein and CpG–ODN as a nasal adjuvant showed enhanced
pulmonary pathology after a live-virus challenge despite an increased humoral
neutralizing-Ab response [174]. This observation has not yet been confirmed in non-
human primates.
In the field of BRSV, CpG–ODN appeared to be a suitable candidate adjuvant for
inactivated vaccines. Used with FI-BRSV vaccine in calves, CpG–ODN increased
the number of IFN-g-secreting cells in the peripheral blood and bronchotracheal
lymph nodes, enhanced the BRSV-specific serum IgG2 response and decreased the
multiplication of BRSV in the lung tissue upon challenge of the vaccinated animals
[175].
The capacity of dendritic cells (DCs) to present exogenous antigens into the MHC
class I pathway and to induce CTL responses [176] could also represent a new and
promising strategy for the development of new vaccines. Several molecules such as
Fc receptors, C-type lectins, DC-SIGN mannose receptor and CD205, which have
been shown to increase the capture and endocytosis of viral antigens by dendritic
cells, have not yet been tested with RSV. Recently, nanoparticles of selected sizes
(in the range of 20–120 nm) were combined with domains of RSV proteins G or
M2.1 and assessed in vivo for uptake by DCs. Results showed that the balance
between the Th-1 and Th-2 immune responses to vaccination was influenced by
nanoparticle size, which could be useful for the development of effective vaccines
against RSV [177].
4.3. Live virus vaccines
Since natural infection with RSV does not predispose to severe disease upon
subsequent exposure to the virus, vaccine development has focused on live vaccines
administered by a mucosal route, because they best mimic natural infection.
Intranasal immunization with a live attenuated RSV vaccine should also induce
both systemic and local immunity and therefore protect against upper as well
as lower respiratory diseases. In addition, the mucosal route of immunization
has the advantage of reducing the immunosuppressive effects of maternally derived
Abs.
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4.3.1. Classical live attenuated vaccines
Live attenuated vaccines against BRSV have been on the market since the 1970s.
Attenuation was essentially obtained by serial passages of the virus in cell culture.
Until 2006, these vaccines were administered by the parenteral route for fear of
reversion to virulence, horizontal transmission, potential recombination between
vaccine and wild-type field strains, and possible infection of humans. Live attenuated
BRSV vaccines are currently used today and show the same efficacy as inactivated
vaccines. In experimental studies in calves, these vaccines elicited a partially or
completely protective immune response against BRSV challenge [178–181]. In-the-
field studies have shown a variable effect of live attenuated BRSV vaccination on
prevalence of clinical disease, needs for treatment or productivity of young calves,
weaned animals and cows, perhaps related to variations in virus prevalence or prior
exposure of the animals to the virus [182–185].
As recent studies suggested that HRSV and BRSV display a highly restricted host
range in vivo [186], a new live attenuated BRSV vaccine administered by the
intranasal route has been commercialized in 2006 [187]. Virus excretion was
significantly reduced when vaccinated calves were challenged with a wild BRSV
strain 10 days after vaccination [187]. However, transmission of the attenuated
vaccine strain was observed from vaccinated to unvaccinated calves. Partial clinical
protection was demonstrated in this study when vaccinated calves were challenged 21
days after immunization [187].
BRSV has also been considered as a possible vaccine against HRSV [186]. Wild-
type BRSV was not directly tested as a vaccine in humans. However, a genetic
recombinant BRSV vaccine was tested in chimpanzees and shown to be over-
attenuated and not to protect the animals against challenge with HRSV, despite its
high levels of replication in the upper respiratory tract [186]. Adaptation to the new
host was improved by replacing the G and F genes of BRSV with their HRSV
counterparts, but the resulting chimeric virus still remained overattenuated [186].
For this reason, BRSV is generally not considered as a suitable candidate vaccine for
HRSV.
In humans, several strategies for the development of an attenuated HRSV vaccine
were originally explored in the 1960s, including the creation of host range mutants,
cold-passaged (cp) mutants, and temperature-sensitive (ts) mutants [110,188–190].
To summarize, these vaccine candidates were either underattenuated (cp and ts-1) or
overattenuated (RSV ts-2), and reversion to the wt phenotype was observed in viral
isolates obtained from children vaccinated with the RSV ts-1 mutant. Importantly,
enhancement of disease was not observed when infants who received RSV ts-1 or cp-
RSV were naturally infected with wt HRSV [191,192]. The most promising mutants
(cpts) were obtained when wild-type HRSV strain A2 (subgroup A) was first
subjected to extensive cold-passage in vitro, resulting in a moderately attenuated
mutant called cp-RSV, which was then subjected to two rounds of chemical
mutagenesis to yield temperature-sensitive (ts) derivatives. This strategy generated
candidate vaccines with a range of shut-off temperatures (35–37 1C) that displayed a
spectrum of attenuation in rodents and non-human primates [134,193–195]. The cpts
248/955 and 530/1009 vaccines retained the ts phenotype after prolonged replication
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in RSV-seronegative children, indicating a stable ts phenotype [196]. These candidate
vaccines were shown to protect chimpanzees against challenge with wt RSV
[134,194,196] and to considerably restrict challenge virus replication in the upper and
lower respiratory tract of seropositive animals [134], indicating that they could
induce protective immune responses in the presence of passively acquired RSV Abs.
Several promising cpts mutants were shown to induce a local and systemic protective
immune response in seropositive as well as seronegative children [197,198]. However,
to date, none of these vaccines, including the highly attenuated cpts-248/404, seems
to be sufficiently attenuated to be used in 1–2-month-old RSV-naı¨ve infants [198].
4.3.2. Live RSV vaccines derived via genetic engineering
The application of reverse genetics to RSV [199] has opened new ways to develop
live attenuated viruses. First, it has provided significant information about the role
of viral proteins in pathogenicity and the interplay of viral proteins with components
of the host cell immune response. Second, it is a powerful tool to introduce combined
attenuating mutations or deletions in the RSV genome to fine-tune the level of
attenuation and to produce vaccines sufficiently infectious and immunogenic yet
attenuated and genetically stable.
Reverse genetics was first used to evaluate the individual effects of the mutations
observed in the cpts candidate vaccines, by introducing single attenuating mutations
into RSV cDNA [200]. The combinations of several mutations and deletions were
then tested in vitro and in vivo. The most promising candidate, designated rA2cp248/
404/1030/_SH, is a recombinant version of cpts-248/404 that has been further
attenuated by the inclusion of an additional ts mutation, called 1030, from cpts-530/
1030, as well as by the deletion of its SH gene. This strain was more thermosensitive
and attenuated and resulted in a lower level of virus shedding in seronegative
children than cpts-248/404. This is the first RSV vaccine candidate to be sufficiently
attenuated to be tested in young infants, although protective immunity against wild-
type RSV challenge was not evaluated in this study [201].
The deletion of non-essential genes represents another promising strategy for
vaccine development, either on their own or in combination with point mutations.
Five genes, namely NS1, NS2, SH, G, and M2-2, can be deleted or silenced without
much effect on virus yields in vitro [199,202–207]. The range of attenuation of HRSV
deletion mutants was compared in chimpanzees and mutants could be ranked in
order of increasing attenuation as follows: DSH-DNS2-cpts-248/404-DNS1-DM2-2
[205,208].
Deletion of the G gene was thought unlikely to be useful since G was one of the
antigens that elicited the greatest and most frequent immune responses [204,205].
Recombinant BRSV lacking the G protein (DG) was nevertheless tested by the
intranasal route in calves and appeared to be overattenuated. More interesting
results were obtained with BRSV expressing only the membrane-anchored form of
the G protein. This mutant efficiently replicated in the nasopharynx of calves but
viral load was reduced in the lungs. Intranasal and intratracheal inoculation induced
a complete protection against subsequent BRSV challenge [30]. However, this strain
differs from wild-type BRSV by only one single-point mutation, facilitating potential
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reversion. Protection and safety was also demonstrated in the mouse model with an
HRSV mutant lacking the ability to secrete the G protein [209].
Several other deletion mutants have been tested. The SH gene is not essential for
the replication of either HRSV or BRSV in vitro. In vivo, BRSV DSH replicated as
efficiently as wild-type virus in the bovine nasopharynx but was attenuated in the
lungs [206,210]. The immunogenic potential of the BRSV DSH strain has not yet
been evaluated in calves. Immunization of chimpanzees by the intranasal and
intratracheal routes with a HRSV DSH strain-induced seric titre of virus-
neutralizing Abs comparable to those induced by wild-type HRSV [208]. The
HRSV DSH strain was shown to be moderately attenuated.
HRSV mutants with deletions of the NS2 (DNS2) or NS1 (DNS1) genes induced
serum-neutralizing Ab levels comparable to or slightly lower than those induced by
wild-type HRSV when tested in chimpanzees but clinical protection was not tested in
this study [205]. Experiments performed in seronegative calves with BRSV DNS1 and
DNS2 showed that intranasal and intratracheal vaccination induced a specific Ab
response, primed BRSV-specific CD4+ T cells and protected calves against a
subsequent challenge with a virulent strain of BRSV [211]. The DNS2mutant seemed
to induce a stronger immunity than DNS1 in calves.
Silencing the M2-2 ORF resulted in a virus in which transcription and antigen
expression was increased, whereas RNA replication and virus production were
decreased. This regulation of RNA replication could provide a new phenotype that
might increase vaccine immunogenicity. Deletion of M2-2 in HRSV indeed produced
a virus that was attenuated and immunogenic in chimpanzees [212] and African
green monkeys [213,214]. No such deleted mutants were tested for BRSV.
Two points must be emphasized regarding these studies. First, in the chimpanzee
model of HRSV vaccination, attenuation was only estimated on the basis of
reduction of virus excretion in the upper and lower respiratory tracts of vaccinated
and infected animals. Actually, due to the limited availability of animals, challenges
were performed with a non-virulent strain and clinical protection was therefore not
fully investigated. In this context, the BRSV model of vaccination may provide a
more accurate information. Second, deletion mutants have only been tested so far in
seronegative animals: we do not know the impact of maternal Abs on their
immunogenicity and, consequently, on their possible efficiency in the field.
Other genetic approaches have been derived from studies on RSV pathogenicity.
The HRSV G protein was shown to be a structural and functional mimetic of
fractalkine [215], a proinflammatory CX3C chemokine that mediates leucocyte
migration and adhesion. This mimicry interferes with the host immune response
[216,217] and is a factor in pathogenesis during HRSV infection [218–220].
Mutagenesis or deletion of the CX3C motif in G did not affect virus growth in
vitro or infectivity in mice. A similar approach was performed with the F protein of
BRSV. The cleavage of BRSV F0 protein during the virus replication cycle at two
sites of the sequence results in the formation of the F1 and F2 subunits and in the
release of a small 27-mer peptide, pep27 [221,222]. This peptide is further converted
into a virokinine, which induces smooth muscle contraction in vitro, and may
therefore contribute to bronchoconstriction in vivo [223]. Recombinant BRSV with
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mutations that abolished cleavage at the second site (rFCS2) or from which pep27
was deleted (Dp27) were produced. Intranasal and intratracheal inoculation of these
two recombinants into calves induced a priming of BRSV-specific T cells and a
protective immune response similar to that induced by wt virus [210], despite a 10-
fold lower BRSV-specific neutralizing Ab titre with FCS-2 than with Dp27 or wild-
type. Reverse genetics was also used to increase the efficiency of protective antigen
expression by moving the G and F genes from their natural positions in the genome
as the seventh and eighth genes in the gene order to promoter–proximal positions,
resulting in an increase in their expression [224]. It was also possible to further
increase their levels of expression by codon optimization.
Finally, it is possible to insert a small gene in the RSV genome, like genes
expressing immunomodulatory proteins, so as to increase the immune response to
the virus. For example, insertion of the granulocyte-macrophage colony-stimulating
factor (GM-CSF) gene in the RSV genome resulted in a dramatic increase in the
number of pulmonary DCs and macrophages in mice following intranasal
inoculation of the recombinant [225].
4.4. Live recombinant vaccines
This approach was evaluated initially in BALB/c mice with recombinant vaccinia
viruses (VV) expressing RSV proteins. VV-M2 conferred short-lived protection in
BALB/c (H-2d) mice while VV-F and VV-G each induced a long-term protection
against wt RSV challenge in BALB/c mice of three major histocompatibility complex
haplotypes [226]. However, these recombinants were poorly immunogenic when
administered parenterally to chimpanzees [227] and were considered to be not
suitable for vaccination against HRSV. For BRSV, modified vaccinia virus Ankara
(rMVA)-based vaccine candidates expressing the F protein, in combination or not
with the G protein, were recently shown to induce BRSV-specific IgGs and CD8+ T
cell responses as well as partial protection after challenge [228].
Regarding HRSV, the more advanced project concerns heterologous mono-
negaviruses as vectors for RSV antigens. One major advantage would be that the
vector itself is a needed vaccine rather than simply a carrier. Since human
parainfluenza virus type 3 (HPIV3) is second only to RSV in importance as a
paediatric viral respiratory tract pathogen, a chimera was constructed between
HPIV3 and its antigenically related bovine counterpart, BPIV3. BPIV3 is attenuated
in primates due to a natural host range restriction and was found to be
immunogenic, safe and genetically stable in seronegative infants and children
[229]. First, BPIV3 was modified by reverse genetics so that its major protective
antigen genes F and HN were replaced with the homologous genes from HPIV3.
This chimeric virus, rB/HPIV, combines the major protective antigens of HPIV3
with the attenuated backbone of BPIV3 [230] and is a potential vaccine candidate for
HPIV3. Next, the HRSV G and F glycoprotein genes were inserted singly or together
into rB/HPIV3 at a promoter–proximal insertion site, so as to maximize their
expression [231]. The resulting chimeric rB/HPIV3-RSV viruses replicated efficiently
in vitro and expressed high levels of the RSV G and F glycoproteins [232]. When
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inoculated into the respiratory tract of rhesus monkeys, they were somewhat more
attenuated than their rB/HPIV3 parent but nonetheless proved to be highly
immunogenic against both HRSV and HPIV3 [231]. Immunogenicity and protective
effects of similar rB/HPIV3 constructions containing soluble or native HRSV F
protein were also demonstrated in African green monkeys and hamsters [233,234].
Finally, mixing two rB/HPIV3-RSV recombinants with HRSV subgroups A and B
specificity, respectively, provided a trivalent paediatric vaccine against RSV-A, RSV-
B and PIV-3. Interestingly, the rB/HPIV3-RSV chimeric viruses were not neutralized
by RSV-specific Abs, raising the possibility that a PIV-vectored RSV vaccine might
be particularly useful as a booster immunization in infants previously immunized
with an RSV vaccine.
In a similar way, a bovine herpesvirus-1 (BoHV-1) recombinant expressing the G
protein of BRSV was constructed by insertion of a synthetic G gene behind the
BoHV-1 gE promoter, to give a gE-negative, BoHV-1/G recombinant. This
recombinant induced virological protection in calves against BRSV challenge but
expression of the G protein of BRSV increased the virulence of BoHV-1 for calves
after vaccination [235].
4.5. DNA vaccines
DNA vaccination is an efficient way of inducing CD8+ T-cell responses, although
responses are generally weaker than those induced by live vectors. However, DNA
vaccines offer several advantages. They are simple to store and administer and
generate endogenous synthesis of antigen, allowing encoded proteins to enter the
major histocompatibility complex (MHC) class I presentation pathway and securing
efficient induction of CD8+ T cells [236]. Furthermore, there is evidence that DNA
vaccines may circumvent the inhibitory effects of maternal Abs [237], although this
has not been a consistent finding [238–240]. However, DNA vaccines do not appear
to be significantly immunogenic in humans, so the utility of this strategy for
immunizing human neonates is unclear at this time.
The ability of DNA expressing either the F or G protein to protect against
infection has been successfully tested for HRSV in mice or cotton rats and for BRSV
in calves [236,241,242]. In addition, DNA immunization with the G gene did not
significantly enhance pulmonary pathology following virus challenge [243,244].
When tested in non-human primates, HRSV DNA vaccines were not highly
immunogenic and required one or more booster immunizations that would be
difficult to administer to infants in the short-time window between birth and the
peak of serious RSV disease. Regarding BRSV, the protection of calves afforded by
intramuscular or intradermal vaccination with BRSV DNA encoding the F
glycoprotein was similarly not as great as that induced by prior BRSV infection
[245]. Serum RSV Abs of calves vaccinated with DNA-F developed more slowly
when compared with those previously infected with BRSV and only the
intramuscular route primed for a rapid BRSV-specific IgA response after viral
challenge [245]. Combination of genes and codon optimization may improve efficacy
of vaccination as recently shown by Boxus et al. [84]. In this study, two
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administrations of codon-optimized plasmids encoding the BRSV F and N proteins
elicited a Th-1 biased immune response, but again protection of calves against a
highly virulent challenge was not complete in spite of a drastic reduction of virus
replication in the host [84].
In all these studies, the immunization regimens required large quantities of
DNA. Therefore gene-gun immunization, which allows one to use much smaller
quantities of DNA, was tested for HRSV with DNA encoding the F or G proteins
or the Kd-restricted 282–90 epitope of M2-2. This technique was shown to be
more immunogenic [246] and to protect mice against RSV infection [247–249].
However, gene-gun immunization with DNA-F or DNA-G was associated with
an unwanted Th-2-biased response and cutaneous gene-gun immunization of
BALB/c mice with a DNA vaccine encoding the Kd-restricted M2-2 epitope
was followed by non-specific enhancement of RSV disease after challenge [250].
Gene-gun DNA vaccination, therefore, does not appear to be suitable for RSV
vaccination.
4.6. Association of different vaccines
Until recently, vaccination was based on single or repeated administrations of the
same vaccine preparation. A novel strategy involving priming and boosting with
different immunogens has resulted in the generation of unprecedented levels of cell-
mediated immunity. This could be advantageous for new vector delivery systems,
such as plasmid DNA vector or modified Ankara virus (MVA) expressing RSV
antigens since they induced correct cellular and humoral immune responses when
administered individually but were insufficient to provide protection against
challenge. The safety and immunogenicity of the HRSV live attenuated cpts 248/
404 mutant and of the PFP-2 vaccine candidate were tested in a placebo-con-
trolled trial in 60 healthy young adults and 60 healthy elderly subjects using
simultaneous or sequential (cpts 248/404 followed by PFP-2) vaccination sche-
dules. In both age groups, sequential immunization elicited higher RSV F IgG
and IgA titre than simultaneous immunization [197]. Recently, immunization with
BRSV plasmids encoding the F and N proteins was shown to elicit a Th-1 biased
immune response and partial protection in calves against challenge with a highly
virulent BRSV strain. When DNA vaccination was followed by a boost with a
killed BRSV vaccine, protection of the animals was complete without disease
enhancement [84].
5. Conclusions
The basic goal of HRSV and BRSV vaccination is not to prevent RSV infection
but to prevent RSV-associated lower respiratory tract disease. The strategies of
vaccination are however different for HRSV or BRSV. In humans, several factors
complicate the development of an effective and safe vaccine and there still is no
licensed vaccine for prevention of HRSV disease to date. Scientifically, these factors
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also exist for BRSV but vaccines are available because minor risks are acceptable in
livestock. Inactivated or attenuated BRSV vaccines have consequently been
extensively used in Europe for the past 2 decades with no major associated-disease
enhancement observed in the field since 2000. Nevertheless, as for HRSV, obstacles
to BRSV vaccination remain, which include short induced protection, the need to
immunize immunologically immature animals and insufficient efficacy of the vaccine
in the presence of maternal Abs. Efforts are being made to use BRSV attenuated
vaccines or subunit vaccines with mucosal adjuvants by the intranasal route.
Licensure of a live attenuated intranasal vaccine in 2006 is too recent to make
conclusions about the efficacy of the vaccine in cattle.
In this context, the ability to manipulate the HRSV and BRSV genomes and better
understanding of the protective and putative disease-enhancing mechanisms
associated with infection have permitted considerable progress in RSV vaccine
development during the past 10 years. More complete understanding of RSV
immunobiology is still however necessary to understand, in particular, why
immunity to RSV is less complete and durable than, for example, that to influenza
virus. In human vaccine research, recent advances have focused on different HRSV
vaccines such as subunit vaccines with specific CD4+ Th-1 immune activating
adjuvants and on genetically engineered live attenuated vaccines. This diversity must
be considered as an advantage. Indeed, as a number of age-related factors may
influence immunity and severity of disease, it is likely that success will require
different vaccine strategies for infants and the elderly. A successful RSV vaccine for
infants would have to induce a protective response in an immature immune system
in the presence of maternal Abs. In this context, the most promising candidates
for young infants are live engineered attenuated RSV strains and RSV antigens
vectored from a live attenuated HPIV strain that can be used by the mucosal
route. The actual difficulty for these live vaccines is to develop a correct balance
between attenuation and immunogenicity in young infants. In addition, even if
attenuating mutations can be fine-tuned in a reasonably systematic way by reverse
genetics, the level of attenuation specified by a combination of attenuating muta-
tions is not always the sum of individual mutations. Efficacy tests in animal
models using highly virulent challenge strains are therefore required to test HRSV
candidate vaccines. For the elderly, efficacious vaccines would have to over-
come waning immune functions and the presence of neutralizing Abs. Safe
subunits vaccines or sequential combinations of different vaccines are promising
ways but need further investigation. Success of subunit vaccines will essentially
depend on the development of strong adjuvants, which selectively activate
neutralizing Abs, CTL and Th-1 CD4+ T cell responses, as well as mucosal
immune responses.
Finally, production of safe and efficacious vaccine is a major but only one step of
vaccination. Strategies of vaccination and the issue of vaccine storage and delivery
will also have to be addressed. This is particularly true for live attenuated vaccines,
which must currently be stored at 70 1C and are administered as nasal drops. It is
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